10319 results for 'NAMPT Inhibitors'

In the intricate dance between the immune system and cancer, tumors often deploy cunning strategies to evade destruction. A groundbreaking 2025 study in Nature has unveiled a startling new tactic: can

TIGIT (T cell immunoreceptor with Ig and ITIM domains) has emerged as a promising target in cancer immunotherapy and the treatment of autoimmune diseases. As a checkpoint receptor, TIGIT

Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha

Quick Facts About SecukinumabWhat is SecukinumabSecukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune respons

Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli

Quick Facts About TesnatilimabWhat is Tesnatilimab?Tesnatilimab is an anti-CD47 monoclonal antibody designed to block the "don’t eat me" signal used by cancer cells to evade immune respo

Quick Facts About CobolimabWhat is Cobolimab?Cobolimab is a monoclonal antibody that targets TIM-3, a checkpoint protein involved in immune regulation, especially in cancer and autoimmun

Quick Facts About LacnotuzumabWhat is Lacnotuzumab?Lacnotuzumab is a monoclonal antibody targeting CD47, a protein that helps cancer cells evade immune system destruction.What is the mec

Polo-like kinase (Plk1) Polo-like kinase (Plk1), is a serine/threonine kinase that is active during mitosis (Hamanaka et al., 1995). Its name is derived from its origi

Epidermal Growth Factor (EGF) is a protein that stimulates cell growth and differentiation by binding to its receptor epidermal growth factor receptor (EGFR) which triggers ligand-induced d

Key Facts About EnoblituzumabWhat is Enoblituzumab?Enoblituzumab is a monoclonal antibody targeting the B7-H3 protein, which is expressed on the surface of various cancer cells, includin

The CD28 molecule plays a crucial role in amplifying T cell activation, which is critical for mounting effective immune responses against tumors. By engaging with co-stimulatory molecules

The ERK signal transduction pathway stands as a fundamental mechanism in cellular biology, orchestrating a wide array of physiological processes, including cell division, differentiation, and surv

Quick Facts About RuplizumabWhat is Ruplizumab?Ruplizumab is an investigational monoclonal antibody designed to target CD47, a protein that helps cancer cells evade immune detection.What

Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst

Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther

Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat

The recent advances in cancer immunotherapy have brought new opportunities to harness the body’s immune system against tumors. Among these advancements is the targeting of immune checkpoi

Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab

Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Does